COCM
CMPX icon

Charter Oak Capital Management’s Compass Therapeutics CMPX Stock Holding History

Charter Oak Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,483
Closed -$4K – 285
2022
Q2 		$4K Hold
1,483
– – ﹤0.01% 728
2022
Q1 		$2K Buy
+1,483
New +$3.06K ﹤0.01% 864

Other funds holding CMPX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

Charter Oak Capital Management's CMPX Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Compass Therapeutics (CMPX) in Q3 2022, closing a stake of 1,483 shares — an estimated $4K sold.

Charter Oak Capital Management first reported a position in CMPX in Q1 2022 and held it in 2 quarters. The position peaked at $4K in Q2 2022. 38 funds tracked by Wall St. Rank hold CMPX as of Q3 2022.

  • Charter Oak Capital Management reported no remaining Compass Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Charter Oak Capital Management sold 1,483 Compass Therapeutics shares in Q3 2022, an estimated $4K.
  • Charter Oak Capital Management first reported a position in Compass Therapeutics in Q1 2022 and held it in 2 quarters.
  • Charter Oak Capital Management's Compass Therapeutics position peaked at $4K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.